$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2021 Q2 Form 10-Q Financial Statement

#000110465921100414 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.522M $1.710M $2.360M
YoY Change 47.49% 31.54% 60.54%
% of Gross Profit
Research & Development $3.599M $5.694M $5.948M
YoY Change -36.79% 60.21% 72.11%
% of Gross Profit
Depreciation & Amortization $62.00K $50.00K $49.00K
YoY Change 24.0% 51.52% 11.36%
% of Gross Profit
Operating Expenses $3.599M $5.694M $5.948M
YoY Change -36.79% 60.21% 72.11%
Operating Profit -$6.121M -$7.400M -$8.308M
YoY Change -17.28% 52.36% 68.59%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$148.0K $10.00K $190.0K
YoY Change -1580.0% -125.0% -290.0%
Pretax Income -$6.269M -$7.390M -$8.110M
YoY Change -15.17% 50.82% 61.23%
Income Tax
% Of Pretax Income
Net Earnings -$6.269M -$7.394M -$8.114M
YoY Change -15.22% 50.9% 61.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$0.17 -$252.5K -$285.4K
COMMON SHARES
Basic Shares Outstanding 36.32M
Diluted Shares Outstanding 36.32M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.61M $16.19M $14.49M
YoY Change 113.79% 499.63% 132.58%
Cash & Equivalents $30.57M $12.15M $12.47M
Short-Term Investments $4.047M $4.040M $2.020M
Other Short-Term Assets $392.0K $180.0K $280.0K
YoY Change 117.78% -80.43% -77.24%
Inventory
Prepaid Expenses
Receivables $183.0K $260.0K $440.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $35.19M $16.63M $15.21M
YoY Change 111.61% 200.14% 84.21%
LONG-TERM ASSETS
Property, Plant & Equipment $1.054M $918.0K $2.840M
YoY Change 14.81% -72.18% 364.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.048M $2.593M $30.00K
YoY Change 171.81% 8543.33% -99.17%
Total Long-Term Assets $7.048M $2.593M $2.860M
YoY Change 171.81% -21.9% -20.42%
TOTAL ASSETS
Total Short-Term Assets $35.19M $16.63M $15.21M
Total Long-Term Assets $7.048M $2.593M $2.860M
Total Assets $42.24M $19.22M $18.07M
YoY Change 119.73% 116.94% 52.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.000M $4.604M $4.570M
YoY Change -34.84% -47.5% -9.13%
Accrued Expenses $1.712M $2.022M $2.510M
YoY Change -15.33% 98.24% 11.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.059M $8.840M $8.250M
YoY Change -8.83% -16.13% -2.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.004M $560.0K $810.0K
YoY Change 615.0% -80.28% -73.44%
Total Long-Term Liabilities $4.004M $559.0K $810.0K
YoY Change 616.28% -80.32% -73.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.059M $8.840M $8.250M
Total Long-Term Liabilities $4.004M $559.0K $810.0K
Total Liabilities $12.06M $9.399M $9.060M
YoY Change 28.34% -29.75% -21.39%
SHAREHOLDERS EQUITY
Retained Earnings -$162.0M -$132.8M
YoY Change 22.02%
Common Stock $192.3M $142.6M
YoY Change 34.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.17M $9.822M $9.011M
YoY Change
Total Liabilities & Shareholders Equity $42.24M $19.22M $18.07M
YoY Change 119.73% 116.94% 52.48%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$6.269M -$7.394M -$8.114M
YoY Change -15.22% 50.9% 61.41%
Depreciation, Depletion And Amortization $62.00K $50.00K $49.00K
YoY Change 24.0% 51.52% 11.36%
Cash From Operating Activities -$5.329M -$5.662M -$15.03M
YoY Change -5.88% 61.4% 1699.88%
INVESTING ACTIVITIES
Capital Expenditures $28.00K $50.00K $7.000K
YoY Change -44.0% 138.1% 75.0%
Acquisitions
YoY Change
Other Investing Activities -$8.000K -$2.020M -$1.990M
YoY Change -99.6% -243.26% -163.38%
Cash From Investing Activities -$39.00K -$2.070M -$1.994M
YoY Change -98.12% -248.81% -163.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000K 7.414M 28.96M
YoY Change -100.01% 148180.0%
NET CHANGE
Cash From Operating Activities -5.329M -5.662M -15.03M
Cash From Investing Activities -39.00K -2.070M -1.994M
Cash From Financing Activities -1.000K 7.414M 28.96M
Net Change In Cash -5.368M -318.0K 11.94M
YoY Change 1588.05% -84.94% 419.82%
FREE CASH FLOW
Cash From Operating Activities -$5.329M -$5.662M -$15.03M
Capital Expenditures $28.00K $50.00K $7.000K
Free Cash Flow -$5.357M -$5.712M -$15.04M
YoY Change -6.21% 61.86% 1692.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Central Index Key
EntityCentralIndexKey
0001137883
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36318561
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35159977
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity File Number
EntityFileNumber
001-36641
dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address City Or Town
EntityAddressCityOrTown
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
488-0460
dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
dei Trading Symbol
TradingSymbol
BCLI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36318561
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30565000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37829000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
4047000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
4107000
CY2021Q2 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
183000
CY2020Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
304000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
392000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1002000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
35187000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
43242000
CY2021Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
108000
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
26000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5886000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6872000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1054000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1119000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7048000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8017000
CY2021Q2 us-gaap Assets
Assets
42235000
CY2020Q4 us-gaap Assets
Assets
51259000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3000000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5417000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1712000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1261000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
192294000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
184655000
CY2021Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2020Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-162018000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2037000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2655000
CY2021Q2 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1310000
CY2020Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1900000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8059000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11233000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4004000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4562000
CY2021Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4004000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4562000
CY2021Q2 us-gaap Liabilities
Liabilities
12063000
CY2020Q4 us-gaap Liabilities
Liabilities
15795000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
12000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36318561
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35159977
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149087000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35464000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42235000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51259000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7940000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11642000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3599000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5694000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5110000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4066000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2522000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1706000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13050000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15708000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6121000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7400000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-119000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-200000
CY2021Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
148000
CY2020Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-6000
us-gaap Net Income Loss
NetIncomeLoss
-12931000
us-gaap Net Income Loss
NetIncomeLoss
-15508000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6269000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7394000
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.36
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.56
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.17
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.25
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36056391
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27452750
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36318561
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29274130
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-12223000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
390000
CY2020Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
18972000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9957000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8114000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
9011000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
791000
CY2020Q2 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
7411000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7394000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9822000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35464000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
290000
bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
7104000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6662000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
36201000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
240000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6269000
CY2021Q2 us-gaap Shares Outstanding
SharesOutstanding
30172000
us-gaap Profit Loss
ProfitLoss
-12931000
us-gaap Profit Loss
ProfitLoss
-15508000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-6269000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-7394000
us-gaap Depreciation
Depreciation
123000
us-gaap Depreciation
Depreciation
99000
CY2021Q2 us-gaap Depreciation
Depreciation
62000
CY2020Q2 us-gaap Depreciation
Depreciation
50000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
530000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1181000
CY2021Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
240000
CY2020Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
791000
bcli Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-190000
bcli Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-50000
CY2021Q2 bcli Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
103000
CY2020Q2 bcli Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
35000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-727000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-2362000
CY2021Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-405000
CY2020Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-284000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2417000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-10073000
CY2021Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
448000
CY2020Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
33000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-139000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1298000
CY2021Q2 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-318000
CY2020Q2 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
539000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14297000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20691000
CY2021Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5329000
CY2020Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5662000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
58000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
57000
CY2021Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
CY2020Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
18000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
4007000
CY2021Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
11000
CY2020Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
2020000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-76000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4064000
CY2021Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39000
CY2020Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2070000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
CY2020Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
bcli Proceeds From At Market
ProceedsFromAtMarket
7104000
bcli Proceeds From At Market
ProceedsFromAtMarket
26383000
CY2020Q2 bcli Proceeds From At Market
ProceedsFromAtMarket
7411000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9957000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7109000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36372000
CY2020Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7414000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7264000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11617000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5368000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-318000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37829000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
536000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35933000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12471000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30565000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12153000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30565000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12153000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 58.3pt;"><b style="font-size:10pt;font-weight:bold;">D.     </b><b style="font-weight:bold;"> </b><b style="font-size:10pt;font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 82.8pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P12M
CY2020 bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P12M
CY2021Q2 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
328000
CY2020Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
984000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5886000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6041000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
684000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y11M1D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0689
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2102000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1213000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1408000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1365000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
567000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6655000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
614000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6041000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000000.0
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1250000
CY2020Q1 us-gaap Share Price
SharePrice
8.00
CY2020Q1 bcli Warrant Term
WarrantTerm
P3Y
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
250000
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.00
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
151000000
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3393413
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7940000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11642000
CY2020Q2 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
13150000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
530000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1181000
us-gaap Share Based Compensation
ShareBasedCompensation
530000
us-gaap Share Based Compensation
ShareBasedCompensation
1181000
CY2021Q2 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
8620000

Files In Submission

Name View Source Status
0001104659-21-100414-index-headers.html Edgar Link pending
0001104659-21-100414-index.html Edgar Link pending
0001104659-21-100414.txt Edgar Link pending
0001104659-21-100414-xbrl.zip Edgar Link pending
bcli-20210630.xsd Edgar Link pending
bcli-20210630x10q.htm Edgar Link pending
bcli-20210630x10q_htm.xml Edgar Link completed
bcli-20210630xex31d1.htm Edgar Link pending
bcli-20210630xex31d2.htm Edgar Link pending
bcli-20210630xex32d1.htm Edgar Link pending
bcli-20210630xex32d2.htm Edgar Link pending
bcli-20210630_cal.xml Edgar Link unprocessable
bcli-20210630_def.xml Edgar Link unprocessable
bcli-20210630_lab.xml Edgar Link unprocessable
bcli-20210630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending